UBS Group AG Raises Holdings in DBV Technologies S.A. $DBVT

UBS Group AG raised its holdings in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 165,347.3% during the 4th quarter, HoldingsChannel.com reports. The firm owned 244,862 shares of the company’s stock after acquiring an additional 244,714 shares during the quarter. UBS Group AG’s holdings in DBV Technologies were worth $4,694,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. GAMMA Investing LLC boosted its stake in DBV Technologies by 38.4% during the 4th quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock valued at $51,000 after purchasing an additional 744 shares during the last quarter. New York State Common Retirement Fund purchased a new position in shares of DBV Technologies in the 3rd quarter worth $34,000. Two Sigma Investments LP purchased a new position in shares of DBV Technologies in the 3rd quarter worth $167,000. Citadel Advisors LLC purchased a new position in shares of DBV Technologies in the 3rd quarter worth $220,000. Finally, DLD Asset Management LP purchased a new position in shares of DBV Technologies in the 3rd quarter worth $250,000. 71.74% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

DBVT has been the topic of a number of research reports. Citigroup restated an “outperform” rating on shares of DBV Technologies in a research note on Friday, May 1st. Wall Street Zen upgraded DBV Technologies from a “sell” rating to a “hold” rating in a research note on Saturday, May 2nd. Citizens Jmp raised their price target on DBV Technologies from $47.00 to $55.00 and gave the stock a “market outperform” rating in a research note on Friday, May 1st. Finally, Guggenheim restated a “buy” rating and issued a $51.00 price target on shares of DBV Technologies in a research note on Monday, May 4th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, DBV Technologies presently has an average rating of “Moderate Buy” and a consensus target price of $40.25.

DBV Technologies Stock Performance

Shares of DBV Technologies stock opened at $18.57 on Friday. DBV Technologies S.A. has a one year low of $7.53 and a one year high of $26.18. The stock’s fifty day moving average is $20.19 and its 200 day moving average is $19.24. The stock has a market cap of $1.10 billion, a P/E ratio of -4.16 and a beta of -0.96.

DBV Technologies (NASDAQ:DBVT) last announced its earnings results on Thursday, April 30th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.42). DBV Technologies had a negative return on equity of 129.88% and a negative net margin of 2,895.37%.The company had revenue of $0.90 million during the quarter, compared to the consensus estimate of $1.11 million. Analysts predict that DBV Technologies S.A. will post -0.47 EPS for the current year.

DBV Technologies Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.